M&A Deal Summary

Oragenics Acquires Noachis Terra

On May 4, 2020, Oragenics acquired life science company Noachis Terra for 2M USD

Acquisition Highlights
  • This is Oragenics’ 1st transaction in the Life Science sector.
  • This is Oragenics’ largest (disclosed) transaction.
  • This is Oragenics’ 1st transaction in the United States.

M&A Deal Summary
Date 2020-05-04
Target Noachis Terra
Sector Life Science
Buyer(s) Oragenics
Deal Type Add-on Acquisition
Deal Value 2M USD

Target

Noachis Terra

United States
Noachis Terra, Inc. develop and commercialize TerraCoV2, a vaccine candidate which could provide specific immunity from the novel coronavirus (“SARS-CoV-2”), the root cause of coronavirus disease 2019 (“COVID-19”).

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Oragenics

Tampa, Florida, United States
Category Company
Founded 1996
Sector Life Science
Employees5
Revenue 14M USD (2022)
DESCRIPTION

Oragenics is a developer of of novel antibiotics against infectious disease and developing effective treatments for oral mucositis. Oragenics was founded in 1996 and is based in Tampa, Florida.

DEAL STATS #
Overall 1 of 3
Sector (Life Science) 1 of 2
Type (Add-on Acquisition) 1 of 2
Country (United States) 1 of 2
Year (2020) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-06-23 Oragenics - Consumer Probiotic Business

Tampa, Florida, United States

Oragenics, Inc. - Consumer Probiotic Business includes antibiotics for disease.

Sell $2M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-03-09 Biodextris

Laval, Quebec, Canada

Biodextris, Inc. is a contract research organization providing a suite of analytical, process development and CMC consulting services for vaccines and biologics in the clinical stages of development. Biodextris is based in Laval, Quebec.

Buy -
Mergr

Product

Company

Legal